Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience.
1/5 보강
[OBJECTIVE] ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer.
- 표본수 (n) 4
APA
Humble RM, Paturu R, et al. (2026). Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience.. American journal of clinical pathology, 165(1). https://doi.org/10.1093/ajcp/aqaf128
MLA
Humble RM, et al.. "Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience.." American journal of clinical pathology, vol. 165, no. 1, 2026.
PMID
41370001 ↗
Abstract 한글 요약
[OBJECTIVE] ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis.
[METHODS] We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered.
[RESULTS] ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease.
[CONCLUSIONS] Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.
[METHODS] We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered.
[RESULTS] ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease.
[CONCLUSIONS] Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- In Situ Hybridization
- Fluorescence
- Prostatic Neoplasms
- Transcriptional Regulator ERG
- Adenocarcinoma
- Middle Aged
- Aged
- Tertiary Care Centers
- 80 and over
- Immunohistochemistry
- Biomarkers
- Tumor
- Retrospective Studies
- ERG
- fluorescence in situ hybridization
- fusion
- immunohistochemistry
- metastasis
- prostatic adenocarcinoma
- small cell carcinoma
- transdifferentiation
- urothelial carcinoma
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.